Companies: 48,874 Total Market Cap: 132429386156445.04

Hansoh Pharmaceutical Group Company Limited

HKG-3692
Healthcare Drug Manufacturers - Specialty & Generic
Rank #1143
Market Cap 17.86 B
Volume 10.30 M
Price 3
Change (%) 0.21%
Country or region Hong Kong Hong Kong

Hansoh Pharmaceutical Group Company Limited's latest marketcap:

17.86 B

As of 05/19/2025, Hansoh Pharmaceutical Group Company Limited's market capitalization has reached $17.86 B. According to our data, Hansoh Pharmaceutical Group Company Limited is the 1143th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 17.86 B
Revenue (ttm) 1.67 B
Net Income (ttm) 594.62 M
Shares Out 5.95 B
EPS (ttm) 0.10
Forward PE 28.76
Ex-Dividend Date 07/03/2025
Earnings Date 05/27/2025
Market Cap Chart
Data Updated: 05/19/2025

Hansoh Pharmaceutical Group Company Limited's yearly market capitalization.

Hansoh Pharmaceutical Group Company Limited has seen its market value drop from HK$222.55 B to HK$139.73 B since 2020, representing a total decrease of 37.22% and an annual compound decline rate (CAGR) of 10.08%.
Date Market Cap Change (%)
05/19/2025 HK$139.73 B 35.97%
12/31/2024 HK$102.55 B 9.84%
12/29/2023 HK$93.36 B 6.25%
12/30/2022 HK$87.86 B -21.92%
12/31/2021 HK$112.52 B -49.44%
12/31/2020 HK$222.55 B

Company Profile

About Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited is an investment holding company specializing in the research, development, production, and sale of pharmaceutical products in China. Founded in 1995 and headquartered in Shanghai, the company operates as a subsidiary of Stellar Infinity Company Ltd.

Key Therapeutic Areas

  • Anti-infection
  • Central nervous system
  • Oncology
  • Metabolic and autoimmune diseases

Principal Products

  • Branded Medications: Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan
  • Specialty Treatments: Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining
  • Other Offerings: XINYUE, Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, and Punuoan tablets

Strategic Partnerships

Hansoh collaborates with global pharmaceutical leaders through key licensing agreements:

  • GlaxoSmithKline: Development of HS-20089 and HS-20093 for extensive-stage small-cell lung cancer (ES-SCLC).
  • Biotheus Inc.: Bispecific antibody-drug conjugate product development.
  • Merck Sharp & Dohme (MSD): Development of HS-10535, an investigational oral GLP-1 receptor agonist.
Frequently Asked Questions

As of 05/19/2025, Hansoh Pharmaceutical Group Company Limited (including the parent company, if applicable) has an estimated market capitalization of $17.86 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Hansoh Pharmaceutical Group Company Limited global market capitalization ranking is approximately 1143 as of 05/19/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Hong Kong
Founded 1995
IPO Date n/a
Employees 8,989
CEO Huijuan Zhong
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Address 287 Xiangke Road
Shanghai, 201210
China
Website https://www.hspharm.com
People Also Watch
Zoetis
163.66 0.21%
Merck KGaA
129.19 0.21%
Haleon plc
541.86 0.21%
NSE-SUNPHARMA
20.24 0.21%